Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction.
about
Evaluation of chronic kidney disease in chronic heart failure: From biomarkers to arterial renal resistancesImproved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trialIndividualizing pharmacotherapy in patients with renal impairment: the validity of the Modification of Diet in Renal Disease formula in specific patient populations with a glomerular filtration rate below 60 ml/min. A systematic reviewRenal dysfunction, restrictive left ventricular filling pattern and mortality risk in patients admitted with heart failure: a 7-year follow-up studyClinical, biomarker, and genetic predictors of specific types of atrial fibrillation in a community-based cohort: data of the PREVEND study.Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction.Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies.Chronic kidney disease and the risk of heart failure in menImproving prognosis estimation in patients with heart failure and the cardiorenal syndromePrognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial.Optimizing fluid management in patients with acute decompensated heart failure (ADHF): the emerging role of combined measurement of body hydration status and brain natriuretic peptide (BNP) levels.The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction.Right ventricular dysfunction is associated with chronic kidney disease and predicts survival in patients with chronic systolic heart failure.Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trialRenal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myocCystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular eventsSpreadsheet use to calculate creatinine clearance from serum creatinine.Iohexol clearance is superior to creatinine-based renal function estimating equations in detecting short-term renal function decline in chronic heart failure.Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis.eGFR and Outcomes in Patients with Acute Decompensated Heart Failure with or without Elevated BUN.A Comparison of Traditional and Novel Definitions (RIFLE, AKIN, and KDIGO) of Acute Kidney Injury for the Prediction of Outcomes in Acute Decompensated Heart FailureNatriuretic peptides in chronic kidney disease.V2 receptor antagonism with tolvaptan in heart failure.High prevalence of stage 3 chronic kidney disease in older adults despite normal serum creatinine.The simplified modification of diet in renal disease equation as a predictor of renal function after coronary artery bypass graft surgery.Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rateAssociation of chronic kidney disease with outcomes in chronic heart failure: a propensity-matched study.Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial.Renal dysfunction is associated with shorter telomere length in heart failure.Activation of a novel natriuretic endocrine system in humans with heart failure.Chronic kidney disease: Prognostic marker of nonfatal pulmonary thromboembolism.Emerging therapies for heart failure: renal mechanisms and effects.Treatment of congestion in heart failure with diuretics and extracorporeal therapies: effects on symptoms, renal function, and prognosis.Current and novel renal biomarkers in heart failure.Can we prevent or treat renal dysfunction in chronic heart failure?Clinical utility of biomarkers in chronic kidney disease and chronic heart failure.Epidemiology and importance of renal dysfunction in heart failure patients.Prognostic value of biological markers in myocardial infarction patients.
P2860
Q28084462-6D207B13-4713-4773-9C6F-9A7BD237BDA4Q28278243-ADF923C3-5A9F-4BE2-B503-DEC614D893D8Q28543876-68ACC752-623E-45AC-8D62-6DE5BDEDA9BAQ31145367-4EA5484A-3296-4F11-ADFC-BB22255EE63AQ31160340-03C544A3-683D-4259-8816-9F6517088A2CQ33529398-565B8CEF-8EAC-49BD-83FB-EFD1B20BC508Q33791046-62B85710-269C-440A-A508-0EF437A9A2FFQ34019056-F9B29E4E-5E13-4F5C-91F3-28695EE2DC41Q34687362-376F7AAE-1E26-44D1-AF47-CAD3D227D8A0Q35020305-11A7CDC2-0939-4FFE-89A3-4C7984AF2AFCQ35128552-329B9D26-05DB-430A-AD7A-2721259F79F4Q35151512-5E57531F-D0B6-4D7D-AFEF-552A3D0E05DDQ35549440-D598CDB5-C03B-4C3C-A7B8-0F081DAB95FAQ35569452-EF389771-53DB-474B-9D24-DFBDBDF5CD61Q35770959-67F4EAA9-C801-41CF-864D-D55CD9D23CF5Q36179462-27ED826D-210A-4829-B7F5-4517E0A6E7F2Q36188016-62A663CC-6228-491F-8789-11BBA3F21355Q36345739-7608EC8C-0702-41E9-B387-30A69C79E751Q36375836-511BA4EB-9DDA-41B2-98CB-A661ED4A354CQ36453374-ED304309-93D1-4285-81CA-10B64D97BC97Q36576768-20434308-7A54-43DF-B5FD-88C1CDA12A45Q36686994-AC929E60-3C66-4DCE-9B86-33EB728398F0Q36917527-705CE588-53CA-4F8D-93D3-3968432FD3B8Q36947290-A81CF314-ADAD-4356-B19B-8941ED5E652DQ36964715-0E9E767F-4DE4-4348-A66F-4051CC452CD1Q37024559-E2EB242F-9552-4913-8A3B-34C62C088855Q37041336-52E8605B-ABA3-4C14-9F92-132BF7103E30Q37280350-EF440BC6-89AC-4531-9FA6-E4B8843F2F99Q37290759-BDF77B2D-E8B6-472A-92AF-FBF635B8E2FFQ37312535-35B8988D-39D9-4609-BE89-82F2314CAF84Q37363993-97BEB07E-7D74-4610-A0B3-B3FD424AC977Q37461939-B44A1C42-7183-4586-A661-127ADEC696A3Q37680552-0AB8C50A-0D5F-4803-B931-51C52F66B19FQ37783956-244F79EB-CDCD-42EB-8D06-D4E92834BA56Q37874161-D9D0E902-6CB4-4F4E-BB49-3859AD7F78DDQ37878418-60AE44F1-7F37-4F6D-93CC-48367F714C73Q37893011-1F456754-5F79-48AF-A3B4-06F836DE8E50Q38125509-98041A47-F665-496C-A669-BF12F4CDFDAEQ38149800-9EA2AD50-9E4B-4DB9-8AD5-F7EB016E3800Q38188531-361F737D-B93F-42E3-90E5-0DBEA5EA8956
P2860
Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Drawbacks and prognostic value ...... lure and systolic dysfunction.
@en
Drawbacks and prognostic value ...... lure and systolic dysfunction.
@nl
type
label
Drawbacks and prognostic value ...... lure and systolic dysfunction.
@en
Drawbacks and prognostic value ...... lure and systolic dysfunction.
@nl
prefLabel
Drawbacks and prognostic value ...... lure and systolic dysfunction.
@en
Drawbacks and prognostic value ...... lure and systolic dysfunction.
@nl
P2093
P921
P1433
P1476
Drawbacks and prognostic value ...... lure and systolic dysfunction.
@en
P2093
Adriaan A Voors
Gerjan Navis
Hans L Hillege
Tom D J Smilde
P304
P356
10.1161/CIRCULATIONAHA.105.610642
P407
P577
2006-10-02T00:00:00Z